Dear Sir/Ma''am, Please find Financial Results for the quarter and year ended 31.03.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Omkar Pharmachem Ltd reported net total income of Rs. 54.74 lakh for FY2026, broadly flat compared to Rs. 54.23 lakh in FY2025. Profit after tax (PAT) grew significantly to Rs. 20.09 lakh from Rs. 12.18 lakh in the prior year, representing a strong year-on-year increase. The company posted other comprehensive income of Rs. 2,708.43 lakh, largely driven by fair value changes in investments (which surged from Rs. 930 lakh to Rs. 3,638.43 lakh), inflating total comprehensive income to Rs. 2,720.61 lakh. Operating cash flow remained positive at Rs. 22.34 lakh, and the statutory auditor issued an unmodified (clean) opinion. Total equity strengthened to Rs. 3,663.98 lakh from Rs. 943.37 lakh.
The clean audit opinion and positive PAT growth are reassuring for investors. However, the near-flat revenue and the large OCI (likely unrealized investment gains) mean core operational performance remains modest; investors should focus on recurring profitability rather than the inflated total comprehensive income figure.